Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis

The Journal of Clinical Investigation
M E RussellM H Sayegh

Abstract

CTLA4Ig, a fusion protein that blocks CD28-B7 costimulation, was studied in a LEW to F344 rat model of chronic cardiac rejection. In rats treated with a single dose of CTLA4Ig (0.5 mg intraperitoneally) 2 d after transplantation, allografts survived significantly longer ( > 70 d in 64%) than in untreated controls or rats treated with control Ig (all rejected within 25 d). Only 25% of grafts from rats treated with a single, high dose of cyclosporine A (25 mg/kg, 2 d after transplantation) survived longer than 70 d. Reverse transcriptase PCR and immunostaining analyses of tissue from 75-d, CTLA4Ig-treated allografts showed reduced expression of the T cell factor IFN-gamma and macrophage activation factors monocyte chemoattractant protein-1, inducible nitric oxide synthase, and galactose/N-acetylgalactosamine macrophage lectin, as well as TGF-beta. Grafts from longterm survivors ( > 120 d) treated with CTLA4Ig showed significant reductions in the frequency and severity of arteriosclerosis in comparison with cyclosporine A-treated rats. Thus, T cell activation is a proximal event in the cascade that culminates in the arteriosclerosis of chronic rejection. Strategies for blocking T cell costimulation may help prevent chronic rejecti...Continue Reading

References

May 11, 1992·Transplantation·D H AdamsM J Karnovsky
Sep 1, 1991·The Journal of Experimental Medicine·P S LinsleyJ A Ledbetter
Oct 1, 1994·Current Opinion in Immunology·V A BoussiotisL M Nadler
May 1, 1995·The Journal of Experimental Medicine·M H SayeghL A Turka
Jun 27, 1994·Transplantation·T C PearsonC P Larsen
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·M E RussellM J Karnovsky
Jan 1, 1993·Annual Review of Immunology·P S Linsley, J A Ledbetter

❮ Previous
Next ❯

Citations

Aug 1, 1997·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·F HoffmannS Bulfone-Paus
Nov 12, 2003·Pharmacology & Therapeutics·Farzad Moien-AfshariIsmail Laher
Dec 26, 2001·Transplantation Proceedings·H K RollsE V Fedoseyeva
Nov 15, 2002·Transplantation Proceedings·Y MatsunoH Hirose
Feb 1, 1997·Transplantation Proceedings·P HäyryA Räisänen-Sokolowski
Oct 8, 1999·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·A Räisänen-SokolowskiM E Russell
May 7, 1999·Kidney International·R B MannonT M Coffman
Jun 26, 2002·Kidney International·Roslyn B MannonThomas M Coffman
Oct 5, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·N KojimaH Senoo
Nov 21, 2000·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·N IchikawaN Murase
Jun 19, 1998·The New England Journal of Medicine·M H Sayegh, L A Turka
Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·M Suthanthiran
Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·H AzumaM H Sayegh
Aug 24, 1999·Current Opinion in Nephrology and Hypertension·W W Hancock
May 10, 2005·Transplantation·Hisanori KashizukaMohamed H Sayegh
Dec 16, 2010·Current Opinion in Organ Transplantation·Gilles BenichouJoren C Madsen
Mar 13, 2001·Annual Review of Immunology·B Salomon, J A Bluestone
Apr 25, 2000·Annual Review of Medicine·M Weis, W von Scheidt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.